Pure Appl. Chem., 2007, Vol. 79, No. 4, pp. 469-479
http://dx.doi.org/10.1351/pac200779040469
Development of huperzine A and B for treatment of Alzheimer's disease
CrossRef Cited-by Linking
- Ding Rui, Lu YunYu, Yao HeQuan, Sun BingFeng, Lin GuoQiang: A new approach to the bicyclo[3.3.1]nonane framework of huperzine A-like molecules via palladium-catalyzed intramolecular γ-arylation. Sci China Chem 2012. <http://dx.doi.org/10.1007/s11426-011-4480-y>
- Mehta Mona, Adem Abdu, Sabbagh Marwan: New Acetylcholinesterase Inhibitors for Alzheimer's Disease. International Journal of Alzheimer s Disease 2012, 2012, 1. <http://dx.doi.org/10.1155/2012/728983>
- Ha Giang T., Wong Ryan K., Zhang Yan: Huperzine A as Potential Treatment of Alzheimer's Disease: An Assessment on Chemistry, Pharmacology, and Clinical Studies. C&B 2011, 8, 1189. <http://dx.doi.org/10.1002/cbdv.201000269>
- Grondal Christoph, Jeanty Matthieu, Enders Dieter: Organocatalytic cascade reactions as a new tool in total synthesis. Nature Chem 2010, 2, 167. <http://dx.doi.org/10.1038/nchem.539>
- Silvestri Romano: Boom in the development of non-peptidic β-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease. Med Res Rev 2009, 29, 295. <http://dx.doi.org/10.1002/med.20132>
- Haigh Julian R., Johnston Scott R., Peppernay Adam, Mattern Patrick J., Garcia Gregory E., Doctor Bhupendra P., Gordon Richard K., Aisen Paul S.: Protection of red blood cell acetylcholinesterase by oral huperzine A against ex vivo soman exposure: Next generation prophylaxis and sequestering of acetylcholinesterase over butyrylcholinesterase. Chemico Biological Interactions 2008, 175, 380. <http://dx.doi.org/10.1016/j.cbi.2008.04.033>